Coefficient | Standard Error | 95% CI | P Value | ||||
---|---|---|---|---|---|---|---|
Total charges | |||||||
DCCM in the post-index period (interaction term) | -0.423 | 0.176 | -0.768 | -0.079 | 0.016 | ||
DCCM group assignment (reference comparison) | 0.803 | 0.138 | 0.533 | 1.073 | < 0.001 | ||
Post-index period (reference pre-index period) | 0.441 | 0.116 | 0.214 | 0.668 | < 0.001 | ||
Baseline HbA1c | -0.107 | 0.025 | -0.156 | -0.059 | < 0.001 | ||
Age | 0.009 | 0.003 | 0.002 | 0.016 | 0.012 | ||
Pre-index diabetes medications | |||||||
Metformin | 0.161 | 0.135 | -0.103 | 0.424 | 0.233 | ||
Insulin use | 0.304 | 0.112 | 0.084 | 0.523 | 0.007 | ||
Pre-index diabetes medications by number of classes (reference 2-3) | |||||||
0-1 | -0.222 | 0.128 | -0.472 | 0.029 | 0.082 | ||
4+ | -0.118 | 0.137 | -0.386 | 0.151 | 0.390 | ||
Comorbidities | |||||||
Retinopathy | 0.521 | 0.184 | 0.160 | 0.883 | 0.005 | ||
Chronic kidney disease | 0.541 | 0.135 | 0.277 | 0.805 | < 0.001 | ||
Black race (reference white) | -0.071 | 0.339 | -0.737 | 0.594 | 0.834 | ||
Male (reference female) | -0.273 | 0.088 | -0.446 | -0.100 | 0.002 | ||
Constant | 7.100 | 0.378 | 6.359 | 7.841 | < 0.001 | ||
Inpatient charges | |||||||
DCCM in the post-index period (interaction term) | -0.142 | 0.237 | -0.608 | 0.324 | 0.550 | ||
DCCM group assignment (reference comparison) | 0.436 | 0.186 | 0.071 | 0.801 | 0.019 | ||
Post-index period (reference pre-index period) | 0.061 | 0.157 | -0.246 | 0.368 | 0.697 | ||
Baseline HbA1c | 0.022 | 0.033 | -0.044 | 0.087 | 0.511 | ||
Age | 0.001 | 0.005 | -0.008 | 0.010 | 0.862 | ||
Pre-index diabetes medications | |||||||
Metformin | 0.082 | 0.182 | -0.275 | 0.438 | 0.653 | ||
Insulin use | 0.204 | 0.151 | -0.093 | 0.500 | 0.178 | ||
Pre-index diabetes medications by number of classes (reference 2-3) | |||||||
0-1 | 0.163 | 0.172 | -0.175 | 0.501 | 0.345 | ||
4+ | 0.238 | 0.185 | -0.125 | 0.600 | 0.198 | ||
Comorbidities | |||||||
Retinopathy | 0.196 | 0.249 | -0.292 | 0.683 | 0.432 | ||
Chronic kidney disease | 0.537 | 0.182 | 0.181 | 0.894 | 0.003 | ||
Black race (reference white) | -0.728 | 0.458 | -1.627 | 0.171 | 0.113 | ||
Male (reference female) | 0.109 | 0.119 | -0.125 | 0.342 | 0.363 | ||
Constant | -0.268 | 0.510 | -1.269 | 0.733 | 0.599 | ||
Outpatient charges | |||||||
DCCM in the post-index period (interaction term) | -0.419 | 0.167 | -0.747 | -0.092 | 0.012 | ||
DCCM group assignment (reference comparison) | 0.750 | 0.131 | 0.493 | 1.007 | < 0.001 | ||
Post-index period (reference pre-index period) | 0.474 | 0.110 | 0.258 | 0.690 | < 0.001 | ||
Baseline HbA1c | -0.115 | 0.023 | -0.161 | -0.069 | < 0.001 | ||
Age | 0.008 | 0.003 | 0.002 | 0.015 | 0.013 | ||
Pre-index diabetes medications | |||||||
Metformin | 0.161 | 0.128 | -0.089 | 0.412 | 0.207 | ||
Insulin use | 0.253 | 0.106 | 0.045 | 0.461 | 0.017 | ||
Pre-index diabetes medications by number of classes (reference 2-3) | |||||||
0-1 | -0.251 | 0.121 | -0.489 | -0.014 | 0.038 | ||
4+ | -0.120 | 0.130 | -0.375 | 0.135 | 0.355 | ||
Comorbidities | |||||||
Retinopathy | 0.561 | 0.175 | 0.218 | 0.904 | 0.001 | ||
Chronic kidney disease | 0.493 | 0.128 | 0.242 | 0.743 | < 0.001 | ||
Black race (reference white) | 0.051 | 0.322 | -0.581 | 0.683 | 0.875 | ||
Male (reference female) | -0.294 | 0.084 | -0.459 | -0.130 | < 0.001 | ||
Constant | 7.171 | 0.359 | 6.468 | 7.875 | < 0.001 |
CI = confidence interval; DCCM = diabetes collaborative care management; HbA1c = hemoglobin A1c.